CAMBRIDGE, Massachusetts, September 5, 2026, 2:15 a.m. EDT — Intellia Therapeutics NASDAQ:NTLA shares barely moved after the gene-editing company unveiled a $400 million credit facility. Only $75 million arrived at closing. Another $100 million still requires the lender’s agreement.
- Intellia closed Friday at $12.74, up 0.5% on 2.8 million shares.
- The initial $75 million draw equals 18.8% of the advertised facility.
- Borrowing costs at least 9.15% annually before additional fees.
- One $30 million tranche depends on an equity-fundraising target.
The deal postpones some near-term dilution. It does not remove that risk. Intellia retains $368.5 million of capacity under an at-the-market stock program.
Investors gave the announcement a muted verdict. Friday’s gain left the stock 3.4% below its August 26 close.
The loan announcement did not break the stock’s range
Intellia closing prices, dollars per share
Prices through the . Source: Nasdaq historical data. U.S. equities are closed for the Labor Day weekend.
Intellia traded between $12.52 and $12.96 Friday. Volume reached 2.8 million shares, below the previous session’s 3.0 million.
The balance sheet was already substantial. Intellia reported $628.4 million in cash and marketable securities at June 30. Existing resources were expected to fund operations at least into 2028.
The upfront loan adds 11.9% to that quarter-end pool before spending. It equals 37.4% of the $200.5 million used in operations during the first half. That comparison is not a runway forecast.
Only 18.8% of the facility was funded at closing
Share of the advertised $400 million facility
Source: Intellia’s September 4 Form 8-K. Percentages calculated by TS2.
Five optional tranches provide another $225 million. They depend on FDA approval, lonvo-z revenue targets and an equity-fundraising target. The final $100 million is uncommitted.
One distinction matters. Intellia expects FDA acceptance of its lonvo-z application in 2026. The next $75 million draw requires approval, a later and less certain event.
The $30 million equity-linked tranche is smaller. Yet its condition weakens the plain-English meaning of “non-dilutive.” The existing ATM program also remains available.
Debt has a visible price. The rate equals one-month SOFR, subject to a 3% floor, plus 6.15 percentage points. That creates a minimum annual rate of 9.15%.
The first $75 million buys flexibility, not a free runway
Balance-sheet and financing measures
Sources: Intellia’s second-quarter Form 10-Q and the September 4 Form 8-K. Ratios calculated by TS2.
At the floor, the first draw costs about $6.9 million yearly. A fully drawn $400 million balance would cost at least $36.6 million. Commitment, administration and exit fees come on top.
OrbiMed also receives first-priority security over substantially all Intellia assets, including intellectual property. Covenants restrict new debt, liens, acquisitions, asset sales and dividends.
The credit rests on a credible clinical catalyst. In the Phase 3 HAELO trial, lonvo-z cut hereditary-angioedema attacks 87% versus placebo. Some 62% of treated patients remained attack-free and therapy-free.
Intellia plans a U.S. launch in the first half of 2027, if approved. Chief Financial Officer Edward Dulac said the financing lets the company “more freely execute our plan to successfully launch lonvo-z in HAE.”
Risks: FDA delay would block an approval-linked tranche. Weak launch revenue could close three more draws. Higher SOFR raises interest expense, while new equity could dilute current holders.
Management next appears at the Wells Fargo healthcare conference on September 9. Investors should watch for an updated cash runway and clearer tranche dates. The filing withheld those deadlines.
